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Abstract
The clinical behavior of endocrine pancreatic tumors (EPTs) is difficult to predict in the absence of
metastases or invasion to adjacent organs. Several markers have been indicated as potential
predictors of metastatic disease, such as tumor size R2 cm, Ki67 proliferative index R2%,
cytokeratin (CK) 19 status, and recently in insulinomas, chromosomal instability (CIN). The goal of
this study was to evaluate the value of these markers, and in particular of the CIN, to predict tumor
recurrence or progression and tumor-specific death, using a series of 47 insulinomas and 24 non-
insulinoma EPTs. From these EPT cases, a genomic profile has been generated and follow-up
data have been obtained. The proliferative index has been determined in 68 tumors and a CK19
expression pattern in 50 tumors. Results are statistically analyzed using Kaplan–Meier plots and
the log-rank statistic. General CIN, as well as specific chromosomal alterations such as 3p and 6q
loss and 12q gain, turned out to be the most powerful indicators for poor tumor-free survival
(P%0.0004) and tumor-specific death (P%0.0113) in insulinomas. The CIN, chromosome 7q
gain, and a proliferative indexR2% were reliable in predicting a poor tumor-free survival in non-
insulinoma EPTs (P%0.0181, whereas CK19 expression was the most optimal predictor of tumor-
specific death in these tumors. In conclusion, DNA copy number status is the most sensitive and
efficient marker of adverse clinical outcome in insulinomas and of potential interest in non-
insulinoma EPTs. As a consequence, this marker should be considered as a prognosticator to
improve clinical diagnosis, most practically as a simple multi-target test.
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Introduction
The clinical behavior of endocrine pancreatic tumors
(EPTs) is difficult to predict on the basis of their
histological features. The presence of metastases is
generally accepted to be the only definitive feature of
malignancy. Therefore, a reliable classification system
is crucial to predict the biological behavior of these
tumors. The currentWHOclassification system is based
on expert opinion, but so far its power in large series of
individual EPT subtypes with a long-term follow-up
remains to be evaluated (Heitz et al. 2004). The
classification criteria comprise the presence of metas-
tases, gross invasion, tumor size, percentage of mitoses,
proliferative index, and vascular invasion. Tumor
resection, the absence of liver and lymph node
metastases, and the presence of multiple endocrine
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neoplasia type 1 (MEN1) syndrome appear to be related
with a better survival rate (Tomassetti et al. 2005).
Several studies have reported potential biomarkers
that are indicators for malignancy of EPTs, such as
a-chain of human chorionic gonadotropin-a (HCG-a),
cyclooxigenase-2 (COX2), p27KIP1, CD99, cytokeratin
19 (CK19), and p53. HCG-a is expressed byw65% of
malignant functioning EPTs. However, since it is also
expressed in benign tumors, this marker is considered
to be of limited value (Heitz et al. 1987, Graeme-Cook
et al. 1990). Up-regulation of COX2 and CK19, and
down-regulation of p27 and CD99 were found to be
associated with Ki67 positive, proliferating tumor cells
(Canavese et al. 2001, Guo et al. 2001, Ohike &
Morohoshi 2001, Rahman et al. 2003, Goto et al. 2004,
Ali et al. 2006). Controversy exists with respect to p53
expression as a marker for malignancy in EPTs. Lee
(1996) suggested no role for p53, whereas Pavelic et al.
(1995) identified p53 overexpression in all the three
cases of malignant insulinomas. We have recently
shown that in insulin-producing EPTs, chromosomal
instability (CIN), identified by analysis of DNA copy
number changes using comparative genomic hybrid-
ization (CGH), is an optimal predictor for malignant
progression (Jonkers et al. 2005). Ki67, p53, and/or
CK19 expression have been found to be associated
with malignancy only in a few individual insulinoma
cases (Jonkers et al. 2006a).
CK19 is a potential immunomarker described to
predict poor survival in EPTs. By comparing classi-
fication criteria and CK19 immunostaining in a series
of 101 EPTs, it was found that CK19 was the only
significant predictor of poor survival (Deshpande et al.
2004). In the study presented here, our aim was to
investigate the reliability of DNA copy number
alterations, including CIN in comparison with CK19
and other clinical parameters to predict poor survival in
EPTs. For this purpose, we have collected follow-up
data of 71 EPT patients, including 47 cases of
insulinoma.
Materials and methods
Tumor material and patient data
Seventy-one EPTs for which a CGH profile was
generated (Speel et al. 1999, 2001, Zhao et al. 2001,
Jonkers et al. 2005, 2006b) and follow-up data could be
obtained, were studied here. They included 47
insulinomas, 6 gastrinomas, 2 glucagonomas, 5
vipomas, and 11 non-functioning tumors. These cases
and their corresponding follow-up data were available
from the archives of the Departments of Pathology of
the University Hospital Zurich, Switzerland, and the
University of Torino, Italy, the Department of Medical
Sciences, University Hospital Uppsala, Sweden, and
the Departments of Pathology of the University
Medical Centers of Rotterdam, Utrecht and Nijmegen,
The Netherlands (Table 1). Ki67 proliferative index
could be determined in 68 tumors and CK19
expression in 50 tumors. The study was done in line
with the code ‘Proper Secondary Use of Human
Tissue’ as implemented by the Dutch Federation of
Biomedical Scientific Societies. The tumors were
classified according to the most recent WHO classi-
fication (Heitz et al. 2004). All tumors were not
associated with the inherited MEN1 syndrome. The
mean age of the 71 EPT patients, including 40 females
and 31 males, was 50.6 years (range 5–82 years).
Follow-up ranged from 0.6 to 21.5 years (mean 7.3
years). The diameter of the insulinomas ranged from
0.5 to 10 cm (mean 2.0 cm). The diameter of the other
functioning EPTs ranged from 2.4 to 8 cm (mean
4.4 cm) and the non-functioning EPTs from 1.2 to
10 cm (mean 5.8 cm).
Twenty-eight of the patients had localized disease at
diagnosis as defined by: 1) the absence of extra-
pancreatic spread of the tumor as evidenced by
Computed Tomography, magnetic resonance imaging
or ultrasound scanning and 2) a tumor size smaller than
2 cm in diameter. Nineteen patients had a tumor with
uncertain behavior, defined by the absence of extra-
pancreatic spread of the tumor, but with a tumor size of
at least 2 cm in diameter, angioinvasion or a
proliferative index of at least 2%. Twenty-four patients
showed metastatic disease at diagnosis.
Detection of CIN by CGH analysis
CGH was used to analyze genome-wide DNA copy
number imbalances in EPTs (Speel et al. 1999, 2001,
Zhao et al. 2001, Jonkers et al. 2005, 2006a,b). This
approach uses differentially labeled tumor and
‘reference’ DNA, which are competitively hybridized
to normal metaphase chromosomes (conventional
CGH) or to mapped genomic clones (array CGH).
The ratio of the fluorescence intensities detected is
indicative of the relative DNA copy number in tumor
versus reference DNA (Fig. 1A; Kallioniemi et al.
1992, Davies et al. 2005, Pinkel & Albertson 2005).
The array CGH analyses were all performed in
Maastricht. The conventional CGH analyses of the
non-insulinoma EPTs were performed in Zurich with
the same resolution as the conventional CGH
performed in Maastricht.
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Table 1 Tumor diagnosis and follow-up status
Tumor type
and nr
Follow-up
time
(months)
Follow-up
status Diagn. CIN Ki67R2% SizeR2 cm
CK19
positive
Meta
at diagn.
Insulinoma
1 216 AW B K K K K K
2 132 AW B K K K K K
3 24 AW B K K K K
4 252 AW B K K K K K
5 96 AW B K K K K
6 120 AW B K K K K
7 132 AW B K K K K K
8 12 AW B K K K K K
9 108 AW B K K K K
10 72 AW B K K K K
11 96 AW B K K K K
12 60 AW B K K K K
13 84 AW B K K K K K
14 36 AW B K K K K
15 156 AW B K K K K K
16 84 AW B K K K K K
17 144 AW B K K K K K
18 72 AW B K K K K
19 36 AW B K K K K K
20 72 AW B K K K K
21 168 AW B K K K K
22 48 AW B K K K K
23 24 AW B K K K K K
24 24 AW B C K K K K
25 48 AW B K K K K
26 60 AW B K C K K
27 72 AW B C K K K K
28 96 AW UB C C C K
29 132 AW UB C K K K
30 144 AW UB K K C K
31 84 AW UB C K C K
32 96 AW UB C K C K K
33 216 AW UB C K C K K
34 12 AW UB C K C K K
35 180 AW M C K K K Meta
36 60 AW M C K C K Meta
37 48 AW M C K C K Meta
38 96 AW M K C K K Meta
39 84 AW M K C C K Meta
40 36 AW M C C C K Meta
41 120 AWD UB C K C K K
42 72 AWD M C C C K Meta
43 120 AWD M C K C C Meta
44 12 DOD M C K C C Meta
45 12 DOD M C K K K Meta
46 12 DOD M C K C Meta
47 24 DOD M C C C K Meta
Non-insulinoma EPTs
Gastrinoma
1 8 AW UB K K C K K
2 131 AW UB K K C K K
3 258 AW UB K K C C K
4 46 AWD UB C C C C K
5 123 AWD M C K C C Meta
6 18 DOD M C C C C Meta
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Table 1 continued
Tumor type
and nr
Follow-up
time
(months)
Follow-up
status Diagn. CIN Ki67 R2% SizeR2 cm
CK19
positive
Meta
at diagn.
Vipoma
1 162 AW M K K K Meta
2 158 AWD UB C K C K K
3 66 DOC M C C C K Meta
4 99 DOD UB C K C K K
5 58 DOD M K K C Meta
Glucagonoma
1 79 DOD M C C C C Meta
2 12 DOD M C Meta
Non-functioning
1 99 AW B K K C K
2 111 AW UB K K C K K
3 108 AW UB K C C K K
4 170 AWD UB C K C K K
5 63 AWD UB C K C C K
6 33 AWD UB C C K
7 96 AWD M C C C K Meta
8 102 AWD M C C C C Meta
9 7 DOD M K C C C Meta
10 72 DOD M C K C C Meta
11 28 DOD M C C C C Meta
Diagn., diagnosis; meta, metastases; B, benign; UB, uncertain behavior; M, malignant; AW, alive without disease; AWD, alive with
disease; DOC, dead of other cause; DOD, dead of disease.C, marker present;K, marker absent; empty cell, not analyzed.
Figure 1 (A) Array CGH procedure with representative examples of array CGH profiles of a benign insulinoma without chromosomal
instability (left) and amalignant insulinomawith chromosomal instability (right). Clones are arranged in the order from chromosome 1
to 22, and X, Y on the X-axis. On the Y-axis, the log2-transformed tumor over reference DNA values are indicated.
Immunohistochemistry for cytokeratin (CK) 19 expression, showing a (B) CK19 positive insulinoma and (C) a CK19 negative
insulinoma with positive staining in ductal cells.
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CIN was defined as the presence of at least eight
chromosomal aberrations by conventional CGH or 20
aberrations of at least 10 Mb by array CGH (Fig. 1A;
Jonkers et al. 2005, 2006a). Sixty-three patient
samples were analyzed by conventional CGH, 26 by
array CGH, and 18 by both methods. In 16 out of these
18 cases, the results matched based on the criteria
described above. In the two other cases CIN was
detected by conventional CGH, and 18 aberrations of
at least 10 Mb were detected by array CGH. These
cases were thus considered to have CIN. Also
individual chromosomal alterations were evaluated
for their predictive value with respect to metastatic
disease or poor survival. Of the chromosomal
alterations detected by conventional CGH, 97.5%
were also detected by array CGH.
CK19 and Ki67 immunohistochemistry
CK19 and Ki67 antigen staining was performed on
4 mm thick paraffin-embedded tissue sections as
described previously (Jonkers et al. 2005, 2006a).
Sections were pretreated with 10 mM citrate buffer
(pH 6.0) in a microwave oven at 600 W for 15 min, and
incubated with a mouse monoclonal antibody directed
against Ki67 (MIB1, 1:100 dilution; DAKO, Glostrup,
Denmark) or human CK19 (RCK108, 1:200 dilution,
MUbio products BV, Maastricht, The Netherlands)
respectively. The primary antibodies were detected by
the avidin-biotinylated peroxidase complex protocol
(ABC Elite kit, Vector laboratories, Burlingame, CA,
USA) and peroxidase activity was visualized using
diaminobenzidine (DAB)/H2O2 (Sigma Chemical Co).
The Ki67 proliferative index was expressed as the
percentage of tumor cells that were immunopositive.
All tumor cases with cytoplasmic staining for RCK108
inR 5% of tumor cells were considered CK19 positive
(Fig. 1B and C).
Statistical analysis
For the statistical analyses of the clinical data SPSS
software was used (SPSS 12.0.1 software, Chicago, IL,
USA). The sensitivity and specificity of each factor for
predicting the presence of metastatic disease were
calculated. The relationship between different par-
ameters was analyzed using the c2 or Fisher exact test,
as appropriate. The level of significance was defined as
P!0.05. All factors with statistical significance in a
univariate analysis were also included in subsequent
multivariate analyses. Survival curves were calculated
using the Kaplan–Meier method. The comparison
between survival functions for the different factors
was assessed with the log-rank statistic.
Tumor-free survival indicated that the patient was
still alive, the primary tumor and/or metastases were
treated and did not show recurrence and/or progression
during follow-up time. When the tumor showed
recurrence and/or progression, a patient was designated
alive with disease (AWD). Tumor-specific death
indicated that the patient died of the disease (DOD)
during the follow-up period.
Results
Parameters to predict metastatic disease
Insulinomas
We examined the reliability of different parameters to
predict metastatic disease, including tumor size, Ki67
proliferative index, CK19 expression, CIN, and
specific chromosomal aberrations. Table 2 shows that
CIN turned out to be the most reliable indicator of
metastatic disease with a sensitivity of 85%, followed
by 7q gain and tumor size. Multivariate analysis
showed that a combination of CIN and size or size
and 6q loss could increase the sensitivity to 92%.
A combination of CIN and Ki67 could even increase
this sensitivity to 100%.
Other EPTs
CIN also proved to be the only significant parameter to
predict metastatic disease in the non-insulinoma EPTs
(Table 2). Multivariate analysis showed an increase in
sensitivity when combining CIN with Ki67 or CK19
expression, or when combining 3p loss and 7q or 14q
gain as markers. Because this tumor group predomi-
nantly comprises tumors with a diameter R2 cm at
presentation, size could not be used as a discriminative
predictor for this purpose.
Parameters to predict tumor-free survival
and tumor-specific death
Insulinomas
The association between the evaluated parameters and
the clinical outcome of insulinomas is presented in
Table 3. Tumor recurrence and/or progression or
tumor-specific death occurred in a minority of
insulinoma patients because of their early presentation
usually followed by resection of the tumor. Four
insulinoma patients died of disease and three were
AWD. Nineteen patients showed CIN including these
seven patients. Six out of seven patients with an event
had a size larger than 2 cm in diameter. Only two of
these patients showed a Ki67 proliferative index of
more than 2% or CK19 expression. Kaplan–Meier
survival analysis underscored the power of CIN and
size as significant markers for poor tumor-free survival
Endocrine-Related Cancer (2007) 14 769–779
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in insulinomas, as shown in Table 4 and Fig 2A and B.
The CK19 expression was also shown to be a
significant indicator of poor tumor-free survival in
insulinomas, although only two out of six insulinomas
with an event (one with tumor-specific death and the
other with tumor progression) showed a positive CK19
staining. None of the other insulinomas showed
expression of CK19.
Also specific chromosomal alterations, including 3p
and 6q loss, and 7q, 12q, and 14q gain were strong
parameters for tumor recurrence and/or progression or
tumor-specific death in these tumors. Fig 2C shows the
Kaplan–Meier curve for chromosome 6q loss as the
most significant chromosomal marker for poor tumor-
free survival. Furthermore, female patients had a
significantly better tumor-free and tumor-specific
survival when compared with male patients
(PZ0.017 and 0.014 respectively), which is in line
with the higher incidence of metastases in male versus
female patients (Danforth et al. 1984). Multivariate
analysis did not improve significance.
Other EPTs
Table 4 shows also the parameters for poor tumor-free
survival and tumor-specific death in the non-insuli-
noma EPT patients. CIN proved to be a reliable marker
for poor tumor-free survival in these patients, followed
by Ki67 proliferative index and chromosome 7q gain
(Fig. 2D and E). CK19 was detected as the most
significant marker for tumor-specific death because of
its positive staining in six out of seven patients with
tumor-specific death (Fig. 2F).
Discussion
In this study, we have examined the value of several
proposed indicators of malignancy and clinical out-
come in a large group of insulinomas and non-
insulinoma EPTs. These parameters include tumor
size R2 cm, Ki67 proliferative index of R2%, CK19
expression, and chromosomal alterations, including
CIN. CIN and specific chromosomal alterations turn
out to be reliable indicators for metastatic disease and
Table 2 Parameters for prediction of metastatic disease in endocrine pancreatic tumors (EPTs)
Insulinomas Sensitivitya (%) Specificityb (%) OR 95% CI P value
Univariate
SizeR2 cm 77 82 15.6 3.3–74.2 0.0005
Ki-67R2% 39 94 10.0 1.6–61.3 0.0189
CK19 17 100 NS
CIN 85 77 17.9 3.3–98.1 0.0005
3p loss 46 91 8.9 1.8–44.3 0.0126
6q loss 54 97 38.5 4.0–372.2 0.0002
7q gain 85 68 11.5 2.2–61.0 0.0039
12q gain 54 85 6.8 1.6–28.7 0.0174
14q gain 62 88 12.0 2.6–55.3 0.0018
Multivariate
CIN and/or Ki-67R2% 100 74 0.0000
CIN and/or size R2 cm 92 74 33.3 3.8–294.3 0.0002
SizeR2 cm and/or 6q loss 92 82 56.0 6.1–516.8 0.0000
EPTs excluding insulinomas
Univariate
SizeR2 cm 100 13 NS
Ki-67R2% 53 83 NS
CK19 67 71 NS
CIN 81 75 13.0 1.7–99.4 0.0254
3p loss 81 63 NS
6q loss 56 63 NS
7q gain 56 75 NS
12q gain 31 88 NS
14q gain 50 88 NS
Multivariate
CIN and/or CK19 94 50 15.0 1.3–174.4 0.0506
CIN and/or Ki-67R2% 88 63 11.7 1.5–91.5 0.0390
3p loss and/or 7q/14q gain 94 50 15.0 1.3–174.4 0.0506
OR, odds ratio; 95% CI, 95% confidence interval.
aPercent of the patients with metastases with the parameter.
bPercent of the patients without metastases without the parameter.
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poor tumor-free survival in insulinoma and non-
insulinoma EPTs, and for tumor-specific death in
insulinomas. CK19 expression is not a strong prog-
nostic indicator in insulinomas, but is the most optimal
indicator of tumor-specific death in the other EPTs.
From previous studies, it has become clear that
malignant progression of EPTs is associated with an
accumulation of genetic alterations (Speel et al. 1999,
2001, Jonkers et al. 2005, 2006a). CIN is defined as the
presence of at least eight chromosomal aberrations
detected by conventional CGH or 20 aberrations of at
least 10 Mb detected by array CGH (Jonkers et al.
2005, 2006a). Although the underlying mechanism
leading to CIN is yet unknown, we have shown here
that this parameter can reliably predict clinical out-
come in insulinomas, and also metastatic disease as
already described before (Jonkers et al. 2005).
Although the sensitivity of CIN to predict tumor-
specific death is high, the specificity is rather low. This
is with high probability due to a number of patients
presenting with tumors of uncertain or malignant
behavior showing CIN of which the tumors have been
treated successfully. Also several frequently occurring
specific chromosomal aberrations, associated with CIN
in insulinomas, are highly effective as prognostic
indicators. In particular, loss of chromosome 3p and
6q, and gain of 12q prove to be very strong parameters
for poor tumor-free survival. This finding underscores
previous results by molecular allelotyping providing
evidence for association of metastatic progression with
chromosome 3p and 6q loss in EPTs (Chung et al.
1997, Hessman et al. 1999, Barghorn et al. 2001a,b,
Rigaud et al. 2001, Guo et al. 2002). Among the
putative candidate genes is FANCD2 which plays a
role in the repair of DNA damage (Jin et al. 2003). This
gene is located on chromosome 3p25, a critical region
of loss in EPTs (Chung et al. 1997). One of the putative
tumor suppressor genes on chromosome 6q24 is lost on
transformation (LOT), a widely expressed zinc finger
protein that inhibits cell growth through induction of
apoptotic cell death and G1 arrest. It appears to be
epigenetically silenced in different types of cancer,
including parathyroid adenomas (Pagotto et al. 2000,
Abdollahi et al. 2003).
Large series of individual EPT subtypes other than
insulinomas have so far not been studied for the
occurrence of CIN. Rigaud et al. (2001) examined a
group of 16 non-functioning EPTs by flow cytometry
and indicated aneuploidy and Ki67 proliferative index
to be the prognostic markers for this tumor subtype. In
contrast, Chung et al. (1998) could not identify a
Table 3 Prognostic parameters and the clinical behavior of
endocrine pancreatic tumor (EPT) patients
Type of tumor (n) AW DOD AWD DOC
Insulinomas (47) 40 4 3 0
Gastrinomas (6) 3 1 2 0
Glucagonomas (2) 0 2 0 0
Vipomas (5) 1 2 1 1
Non-functioning (11) 3 3 5 0
Parameter (n)
Insulinomas
CIN
Present (19) 12 4 3 0
Absent (28) 28 0 0 0
Size
R2 cm (16) 10 3 3 0
!2 cm (31) 30 1 0 0
Ki-67
R2% (7) 5 1 1 0
!2% (40) 35 3 2 0
CK19
Positive (2) 0 1 1 0
Negative (26) 22 2 2 0
EPTs excluding insulinomas
CIN
Present (15) 0 6 8 1
Absent (9) 7 2 0 0
Size
R2 cm (20) 5 6 8 1
!2 cm (1) 1 0 0 0
Ki-67
R2% (9) 1 4 3 1
!2% (12) 5 3 4 0
CK19
Positive (12) 2 6 4 0
Negative (10) 5 1 3 1
AW, alive without disease; DOD, dead of disease; AWD, alive
with disease; DOC, dead of other cause.
Table 4 Significant parameters for predicting tumor-specific
death (DOD) and poor tumor-free survival (DODCAWD) in
endocrine pancreatic tumor (EPT) patients
Marker P value Marker P value
Insulinomas (nZ47)
DOD (nZ4) DODCAWD (nZ7)
CIN 0.0113 CIN 0.0004
3p loss 0.0000 CK19 0.0011
6q loss 0.0009 Size 0.0017
7q gain 0.0269 3p loss 0.0000
12q gain 0.0003 6q loss 0.0000
14q gain 0.0003 7q gain 0.0013
12q gain 0.0000
14q gain 0.0013
EPTs excluding insulinomas (nZ24)
DOD (nZ8) DODCAWD (nZ16)
CK19 0.0314 CIN 0.0012
7q gain 0.0497 Ki-67 0.0074
7q gain 0.0181
DOD, dead of disease; AWD, alive with disease.
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correlation between frequency of allelic loss and
disease stage using genome-wide allelotyping, but
this study was hampered by the small groups of
individual EPT subtypes. In this study, we have been
able to collect follow-up data of 24 non-insulinoma
EPTs from which CGH data were available. CIN
turned out to be the only significant indicator of
metastatic disease and the highest independent pre-
dictor of poor tumor-free survival in this group. For the
prediction of tumor-specific death, gain of chromo-
some 7q and CK19 status were the most reliable
markers. It will be essential to further substantiate
these findings in larger numbers of individual EPT
subtypes in subsequent studies. This is of particular
importance because genetic studies indicate
differences in genetic make-up in the different EPT
subtypes, despite the occurrence of CIN in the
malignant tumors (Speel et al. 1999, Heitz et al. 2004).
In a number of cases, the patients with CIN and a
poor tumor-free survival or tumor-specific death
presented with metastases already at diagnosis.
However, one gastrinoma, two vipomas, one
Figure 2 Kaplan–Meier curves correlating tumor-free survival in insulinomas with (A) CIN, (B) tumor size, and (C) chromosome 6q
loss; the non-insulinoma EPTs with (D) CIN or (E) chromosome 7q gain, and (F) tumor-specific survival with CK19. Significance
scores are indicated.
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insulinoma, and three non-functioning tumors without
detectable metastases at diagnosis presented with
tumor recurrence and/or metastatic progression, or
DOD during follow-up time (Table 1). Another patient
presenting with CIN in an insulinoma of uncertain
behavior also developed metastases after 3 years, but
this patient was excluded from this study because of
the presence of a MEN1 syndrome. This underscores
the reliability of CIN in predicting poor clinical
outcome. Therefore, a simplified test to predict CIN
will be of value in clinical diagnosis of these tumors.
Detection of CIN might change patient management,
e.g. by intensifying clinical follow-up. In addition, it
may help in directing tumor surgery.
As stated above, CK19 expression proved to be the
most optimal marker for tumor-specific death in non-
insulinoma EPTs. These data are in accordance with
the data of Deshpande et al. (2004) and a recent study
by Schmitt et al. (2007), investigating large series of
EPTs, including different subtypes. Our data in this
study, however, strongly indicate that CK19
expression is a suboptimal marker for poor tumor-
free survival in insulinomas. This is probably the
consequence of the low percentage of malignant
tumors with CK19 immunostaining, as also reported
by Ali et al. (2006) and in one of our previous studies
(Jonkers et al. 2006a). So far, only one study was
unable to correlate CK19 expression with malignancy
in EPTs (Albarello et al. 2004). A reason for the
discrepancy between these studies could be the use of
different CK19-directed monoclonal antibodies and/or
criteria for evaluation of immunostaining results.
We have used the RCK108 clone, which is used
by the most other studies and shown to be more reliable
for CK19 analysis than the BA17 clone (La Rosa
et al. 2005).
Of the clinicopathological criteria used in the WHO
classification, tumor size proved to be a very simple
and reliable clinical marker for metastatic disease and
poor tumor-free survival in insulinomas. Although CIN
appeared to be a more significant parameter than tumor
size to predict tumor outcome, the latter parameter is
very useful as a result of the early diagnosis of
insulinomas and often successful treatment. The Ki67
proliferative index is often!2% in insulinomas, and is
therefore not a significant marker for poor tumor-free
survival in insulinomas. In combination with CIN,
however, Ki67 is very useful for predicting metastatic
disease in insulinomas and both metastatic disease and
poor tumor-free survival in non-insulinoma EPTs. In
general, the majority of EPTs are well differentiated
according to the most recent WHO classification. In
this study, only one insulinoma and one glucagonoma
were classified as poorly differentiated with a Ki67
proliferative index ofO10 mitoses per 10 high-power
fields. The respective patients both DOD, thus under-
scoring a poor tumor-specific survival for patients with
poorly differentiated tumors.
In the non-insulinoma EPTs size cannot be
efficiently used to discriminate between benign and
malignant tumors, because the tumor diameter is
usually larger than 2 cm, as also found in this study.
However, size R2 cm has been described as a
predictable marker, because most studies consider
EPTs as one group, with the smaller tumors being
predominantly benign insulinomas and the larger ones
generally comprising the non-insulinoma EPTs with a
more malignant behavior (Speel et al. 1999, Schindl
et al. 2000, Ohike & Morohoshi 2005).
In summary, we have identified CIN as well as
specific chromosomal alterations as the most reliable
indicators of metastatic disease and poor tumor-free
survival in all insulinoma and non-insulinoma EPTs,
and for tumor-specific death in insulinomas. CK19
expression is the most optimal indicator of tumor-
specific death in the non-insulinoma EPTs. Tumor size
is particularly powerful as a predictor of metastatic
disease in insulinomas. The implementation of these
parameters in diagnostic protocols will make the
prediction of the clinical behavior of EPTs more
accurate.
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